Abstract
To describe utilization of a biosimilar product containing filgrastim (Neutromax ®), data of 414 myeloma or lymphoma patients subjected to autologous SCT between 1998 and 2007 were analyzed. Filgrastim was used for mobilization of progenitors (5 days at 300 μg/day) and for the recovery of neutropenia after transplantation (100 μg/day, since day +5). In 2003, the excipient mannitol was replaced by sorbitol. A mean dose of 9.47 × 10 6 CD34 + cells/kg was infused; 100 neutrophils/mm 3 required 5-day treatment; 500 neutrophils/mm 3, 6 days and 1000 neutrophils/mm 3, 7 days. Neutromax ® effect in SCT is similar to reports with other brands. No difference was found between formulations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
